CLINICAL EVALUATION OF CPE IN MAXILLOFACIAL PROSTHESES
颌面修复体中 CPE 的临床评估
基本信息
- 批准号:3219977
- 负责人:
- 金额:$ 7.36万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1983
- 资助国家:美国
- 起止时间:1983-09-20 至 1987-11-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Replacement of parts of the human face and jaws with manmade materials is
the purview of maxillofacial prosthetics. Patients recovering from the
surgical effects of skin cancer, oral cancer, traumatic injuries, and birth
defects are in need of these services. Existing materials used for this
purpose include silicone, polyurethane, and vinyl elastomers. Devices made
of such material often fail in a matter of months due to discoloration,
fraying of feather edges, sagging, or incompatibility with adhesives. A
development program was carried out in 1976-79 at GSRI by Paul D. May and
Luis R. Guerra using chlorinated polyethylene (CPE), an industrial
elastomer produced by Dow Chemical Company. Limited clinical trials
indicated the material to be satisfactory for a more extended trial. This
project will continue this work in four parts: 1. Improve the CPE material
from its 1979 level and measure its physical and biologic properties using
procedure since-developed for use with soft denture liners. Investigate
improved phosphate-bonded, or gypsum molds. 2. Perform a pilot study to
measure the reliability and validity of: a) tests of material performance,
and b) questionnaires of clinician's observations and the patient's
perception of existing maxillofacial prostheses. Use this information to
modify the test instrument for the principal clinical study. 3. Provide
materials and technology to the Dental Department of the Charity Hospital
of New Orleans for clinical trials. Twenty patients needing extraoral
maxillofacial prostheses will be selected. Each will receive two
prostheses, made from the CPE material or from silicone rubber, to be
exchanged every 3 months and worn continuously. 4. Compile data generated
by the clinicians, the patients, and in the laboratory. Determine
superiority of one material over the other by statistically testing the
rating and ranking data. The failing prosthesis will be eliminated from
the study and the patient will be allowed to continue with the successful
one.
用人造材料替换面部和下巴的部分是
颌面部修复术的范围。正在康复的病人
皮肤癌、口腔癌、创伤和分娩的手术效果
缺陷是需要这些服务的。用于此目的的现有材料
用途包括有机硅、聚亚安酯和乙烯基弹性体。制造的设备
这种材料通常由于变色而在几个月内失效,
羽毛边缘磨损、下垂或与粘合剂不相容。一个
发展计划于1976-79年在GSRI由保罗·D·梅和
路易斯·R·格拉使用氯化聚乙烯(CPE),工业
陶氏化学公司生产的弹性体。有限的临床试验
表示材料对于更长时间的试验是令人满意的。这
项目将从四个方面继续这项工作:1.改进CPE材料
从1979年的水平开始,使用以下方法测量其物理和生物特性
此后开发的用于软义齿衬里的程序。调查
改进的磷酸盐粘结或石膏模具。2.进行试点研究,以
测量以下各项的可靠性和有效性:a)材料性能测试;
和b)临床医生观察和患者观察的调查问卷
对现有颌面部假体的感知。使用此信息来
修改主要临床研究的测试仪器。3.提供
捐赠给慈善医院牙科的材料和技术
新奥尔良的临床试验。20名需要口腔外治疗的患者
将选择颌面部假体。每人将得到两个
假体,由CPE材料或硅橡胶制成,
每3个月更换一次,连续佩戴。4.编译生成的数据
由临床医生、病人和实验室进行。测定
通过统计检验一种材料相对于另一种材料的优越性
评级和排名数据。失败的假体将被从
研究和患者将被允许继续进行成功的
一。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lawrence M. Gettleman其他文献
Lawrence M. Gettleman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lawrence M. Gettleman', 18)}}的其他基金
'Multicenter Trial of CPE for Maxillofacial Prosthetics'
“用于颌面修复的 CPE 多中心试验”
- 批准号:
7059328 - 财政年份:2003
- 资助金额:
$ 7.36万 - 项目类别:
'Multicenter Trial of CPE for Maxillofacial Prosthetics'
“用于颌面修复的 CPE 多中心试验”
- 批准号:
6794143 - 财政年份:2003
- 资助金额:
$ 7.36万 - 项目类别:
'Multicenter Trial of CPE for Maxillofacial Prosthetics'
“用于颌面修复的 CPE 多中心试验”
- 批准号:
6893760 - 财政年份:2003
- 资助金额:
$ 7.36万 - 项目类别:
Multicenter Trial of CPE for Maxillofacial Prosthetics
CPE 用于颌面修复的多中心试验
- 批准号:
6612482 - 财政年份:2003
- 资助金额:
$ 7.36万 - 项目类别:
Multicenter Trial of CPE for Maxillofacial Prosthetics
CPE 用于颌面修复的多中心试验
- 批准号:
7226633 - 财政年份:2003
- 资助金额:
$ 7.36万 - 项目类别:
PHOSPHAZENE POLYMERS FOR DENTAL & BIOMEDICAL APPLICATION
牙科用磷腈聚合物
- 批准号:
2130910 - 财政年份:1991
- 资助金额:
$ 7.36万 - 项目类别:
CLINICAL EVALUATION OF CPE IN MAXILLOFACIAL PROSTHESES
颌面修复体中 CPE 的临床评估
- 批准号:
3219976 - 财政年份:1983
- 资助金额:
$ 7.36万 - 项目类别:
CLINICAL EVALUATION OF PNF PERMANENT SOFT DENTURE LINERS
PNF 永久软义齿衬垫的临床评估
- 批准号:
3219149 - 财政年份:1980
- 资助金额:
$ 7.36万 - 项目类别:
相似海外基金
The pathogenesis of ALG14-congenital disorders of glycosylation.
ALG14-先天性糖基化障碍的发病机制。
- 批准号:
23K14967 - 财政年份:2023
- 资助金额:
$ 7.36万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Identifying New Therapeutics and Molecular Mechanisms in Congenital Disorders of Glycosylation.
确定先天性糖基化疾病的新疗法和分子机制。
- 批准号:
10644811 - 财政年份:2023
- 资助金额:
$ 7.36万 - 项目类别:
Investigating the Genotype-Phenotype Relationships that Underlie Congenital Disorders with Cardiovascular Symptoms through Population-scale Analyses
通过人群规模分析研究具有心血管症状的先天性疾病背后的基因型-表型关系
- 批准号:
10724185 - 财政年份:2023
- 资助金额:
$ 7.36万 - 项目类别:
Identifying understudied protein-related glycoproteome disruption in Congenital Disorders of Glycosylation
识别先天性糖基化障碍中尚未研究的蛋白质相关糖蛋白组破坏
- 批准号:
10725869 - 财政年份:2023
- 资助金额:
$ 7.36万 - 项目类别:
Pathogenic Mechanisms of Congenital Disorders of Glycosylation
先天性糖基化障碍的发病机制
- 批准号:
10633548 - 财政年份:2023
- 资助金额:
$ 7.36万 - 项目类别:
Targeting aldose reductase: A Phase IIb/III trial for the novel use of Epalrestat to treat Congenital Disorders of Glycosylation (PMM2-CDG)
靶向醛糖还原酶:依帕司他新用途治疗先天性糖基化障碍 (PMM2-CDG) 的 IIb/III 期试验
- 批准号:
10480649 - 财政年份:2022
- 资助金额:
$ 7.36万 - 项目类别:
Assessment of a potential application of endogenous stem cells to treat congenital disorders
评估内源干细胞治疗先天性疾病的潜在应用
- 批准号:
22K20740 - 财政年份:2022
- 资助金额:
$ 7.36万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Targeting aldose reductase: A Phase IIb/III trial for the novel use of Epalrestat to treat Congenital Disorders of Glycosylation (PMM2-CDG)
靶向醛糖还原酶:依帕司他新用途治疗先天性糖基化障碍 (PMM2-CDG) 的 IIb/III 期试验
- 批准号:
10616658 - 财政年份:2022
- 资助金额:
$ 7.36万 - 项目类别:
O-glycosylation mechanisms of neurological deficits in congenital disorders of glycosylation
先天性糖基化障碍神经功能缺损的O-糖基化机制
- 批准号:
10040788 - 财政年份:2020
- 资助金额:
$ 7.36万 - 项目类别:
O-glycosylation mechanisms of neurological deficits in congenital disorders of glycosylation
先天性糖基化障碍神经功能缺损的O-糖基化机制
- 批准号:
10250486 - 财政年份:2020
- 资助金额:
$ 7.36万 - 项目类别: